Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer
Despite recent improvements to current therapies and the emergence of novel agents to manage advanced non-small cell lung cancer (NSCLC), the patients' overall survival remains poor. Re-challenging with first-line chemotherapy upon relapse is common in the management of small cell lung cancer b...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845541/ https://www.ncbi.nlm.nih.gov/pubmed/23981850 http://dx.doi.org/10.5732/cjc.013.10120 |
_version_ | 1782293321084829696 |
---|---|
author | Khan, Khurum Hanna, Gerard G Campbell, Lynn Scullin, Paula Hussain, Adnan Eakin, Ruth L McAleese, Jonathan |
author_facet | Khan, Khurum Hanna, Gerard G Campbell, Lynn Scullin, Paula Hussain, Adnan Eakin, Ruth L McAleese, Jonathan |
author_sort | Khan, Khurum |
collection | PubMed |
description | Despite recent improvements to current therapies and the emergence of novel agents to manage advanced non-small cell lung cancer (NSCLC), the patients' overall survival remains poor. Re-challenging with first-line chemotherapy upon relapse is common in the management of small cell lung cancer but is not well reported for advanced NSCLC. NSCLC relapse has been attributed to acquired drug resistance, but the repopulation of sensitive clones may also play a role, in which case re-challenge may be appropriate. Here, we report the results of re-challenge with gemcitabine plus carboplatin in 22 patients from a single institution who had previously received gemcitabine plus platinum in the first-line setting and had either partial response or a progression-free interval of longer than 6 months. In this retrospective study, the charts of patients who underwent second-line chemotherapy for NSCLC in our cancer center between January 2005 and April 2010 were reviewed. All the patients who received a combination of gemcitabine and carboplatin for re-challenge were included in the study. These patients were offered second-line treatment on confirmation of clear radiological disease progression. The overall response rate was 15% and disease control rate was 75%. The median survival time was 10.4 months, with 46% of patients alive at 1 year. These results suggest that re-challenge chemotherapy should be considered in selected patients with radiological partial response or a progression-free survival of longer than 6 months to the initial therapy. |
format | Online Article Text |
id | pubmed-3845541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Sun Yat-sen University Cancer Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-38455412013-12-11 Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer Khan, Khurum Hanna, Gerard G Campbell, Lynn Scullin, Paula Hussain, Adnan Eakin, Ruth L McAleese, Jonathan Chin J Cancer Original Article Despite recent improvements to current therapies and the emergence of novel agents to manage advanced non-small cell lung cancer (NSCLC), the patients' overall survival remains poor. Re-challenging with first-line chemotherapy upon relapse is common in the management of small cell lung cancer but is not well reported for advanced NSCLC. NSCLC relapse has been attributed to acquired drug resistance, but the repopulation of sensitive clones may also play a role, in which case re-challenge may be appropriate. Here, we report the results of re-challenge with gemcitabine plus carboplatin in 22 patients from a single institution who had previously received gemcitabine plus platinum in the first-line setting and had either partial response or a progression-free interval of longer than 6 months. In this retrospective study, the charts of patients who underwent second-line chemotherapy for NSCLC in our cancer center between January 2005 and April 2010 were reviewed. All the patients who received a combination of gemcitabine and carboplatin for re-challenge were included in the study. These patients were offered second-line treatment on confirmation of clear radiological disease progression. The overall response rate was 15% and disease control rate was 75%. The median survival time was 10.4 months, with 46% of patients alive at 1 year. These results suggest that re-challenge chemotherapy should be considered in selected patients with radiological partial response or a progression-free survival of longer than 6 months to the initial therapy. Sun Yat-sen University Cancer Center 2013-10 /pmc/articles/PMC3845541/ /pubmed/23981850 http://dx.doi.org/10.5732/cjc.013.10120 Text en Chinese Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission. |
spellingShingle | Original Article Khan, Khurum Hanna, Gerard G Campbell, Lynn Scullin, Paula Hussain, Adnan Eakin, Ruth L McAleese, Jonathan Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer |
title | Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer |
title_full | Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer |
title_fullStr | Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer |
title_full_unstemmed | Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer |
title_short | Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer |
title_sort | re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845541/ https://www.ncbi.nlm.nih.gov/pubmed/23981850 http://dx.doi.org/10.5732/cjc.013.10120 |
work_keys_str_mv | AT khankhurum rechallengechemotherapywithgemcitabinepluscarboplatininpatientswithnonsmallcelllungcancer AT hannagerardg rechallengechemotherapywithgemcitabinepluscarboplatininpatientswithnonsmallcelllungcancer AT campbelllynn rechallengechemotherapywithgemcitabinepluscarboplatininpatientswithnonsmallcelllungcancer AT scullinpaula rechallengechemotherapywithgemcitabinepluscarboplatininpatientswithnonsmallcelllungcancer AT hussainadnan rechallengechemotherapywithgemcitabinepluscarboplatininpatientswithnonsmallcelllungcancer AT eakinruthl rechallengechemotherapywithgemcitabinepluscarboplatininpatientswithnonsmallcelllungcancer AT mcaleesejonathan rechallengechemotherapywithgemcitabinepluscarboplatininpatientswithnonsmallcelllungcancer |